Full Title: Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas (ImmunoSarc)
Status: Active, Recruiting
12 years to 80 years (dedifferentiated chondrosarcoma)
12 years to 40 years (primary metastatic, high-grade osteosarcoma)
Locations: University College London Hospital NHS Foundation Trust
Registry Number NCT03277924
For patients with dedifferentiated chondrosarcoma, this phase 2 study investigates the combination of a targeted therapy tyrosine kinase inhibitor (sunitinib) with immunotherapy (nivolumab).
For patients with primary metastatic osteosarcoma (has spread elsewhere in the body at the time of diagnosis), which is high grade (faster growing) and resectable (can be treated surgically), and who have not undergone previous chemotherapy, a combination of nivolumab and MAP (methotrexate, doxorubicin and cisplatin) chemotherapy is being investigated.
This study is a multinational trial recruiting in Italy, Spain and the UK.
If you would like any more information on clinical trials in general, please contact us at the Bone Cancer Research Trust. For more information on this trial and to understand if you are eligible, please talk to your clinical team.